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ABSTRACT
The most common cause of stroke in children with sickle cell anemia is infarction due to
ischemia. In adults, however, stroke is most commonly hemorrhagic in nature. Other causes of
stroke in patients with sickle cell disease are very rare. In this short communication we describe
a woman with sickle cell anemia responsive to therapy with hydroxyurea who had primary stroke
due to paradoxical embolization caused by a large atrial septal defect. Successful management of
the stroke included surgical closure of the defect with trans-esophageal echocardiographic
guidance. To the best of our knowledge this is the first patient with sickle cell anemia and stroke
due to congenital heart disease that did not require open heart surgery for successful
management.

Key words: sickle cell anemia, stroke, primary stroke, atrial septal defect, patent foramen ovale,
paradoxical embolization
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Introduction
Stroke is a major complication of sickle cell anemia (SS) in children. Its incidence is about 10%
in children with SS less than 10 years of age [1]. Moreover, incidence of silent stroke detected by
magnetic resonance imaging (MRI) could be as high as 35% [2]. Pathophysiologically, these
strokes are most often infarctive in nature secondary to cerebrovascular occlusion. Stroke due to
SS in adults is less common and is usually due to hemorrhage [1]. Risk factors for recurrent
stroke in SS include acute chest syndrome, severe anemia, cerebral vasculopathy, previous stroke
and transcranial Doppler ultrasound velocity > 200 cm/sec [3]. Other rare causes of recurrent
stroke in patients without SS include paradoxical embolization due to patent foramen ovale [4].
In addition, co-existent hyperviscosity or thrombophilia with patent foramen ovale increase the
risk of stroke. This scenario was reported in a child with SS and patent foramen ovale [5]. In this
communication we describe an adult woman with SS and stroke secondary to paradoxical
embolization due to atrial septal defect.

Case Report
A 42-year-old woman with SS has been followed in our adult sickle cell program for 25 years.
Complications of her disease included acute chest syndrome, avascular necrosis of hip joints,
mitral valve prolapse, migraine headaches and frequent vaso-occlusive crises (VOC). She was
enrolled in the multicenter study of hydroxyurea (MSH) when she was 21 years old and has been
on 2500 mg of hydroxyurea (HU) per day since then. She had an excellent response to HU with
no recurrent episodes of acute chest syndrome and infrequent need for blood transfusion. After
starting HU the frequency of VOC requiring hospital admissions decreased from one admission
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every 1 to 2 months to less than one admission per year except when HU was discontinued due
to pregnancy. Her hematologic parameters before and after HU are shown in Table 1.
At the age of 35 years she presented to the emergency room two days after developing abrupt
bilateral blurry vision, left facial numbness and weakness of her left leg. Physical exam was
remarkable for left lower extremity weakness which was more pronounced proximally. Vital
signs were normal. All cranial nerves were intact and there was normal sensation bilaterally.
Computed tomography (CT) scan of the brain showed three foci of hypodensity and magnetic
resonance imaging (MRI) of the brain showed increased signal on T2, FLAIR and diffusion
weighted images within the fronto-parietal deep white matter consistent with infarction in the
border zone of the middle cerebral artery (MCA)-anterior cerebral artery (ACA). Magnetic
resonance angiography (MRA) of the intra-cerebral and extra-cerebral vessels demonstrated
focal narrowing of the right MCA at the trifurcation suggesting an embolic cause. Common
causes of ischemic stroke including hypertension, diabetes, atrial fibrillation, renal disease and
hyperlipidemia were ruled out with routine studies. Her hemoglobin electrophoresis after
admission but before blood exchange transfusion showed HbS of 55% and HbF of 45%.
Transthoracic Doppler echocardiography showed minimal mitral, aortic and tricuspid valves
regurgitation with tricuspid regurgitant velocity (TRV) < 2.0 m/second (normal < 2.5 m/second).
She underwent exchange transfusion 2 days after admission and was started on chronic blood
exchange transfusions with the assumption that she had ischemic stroke due to SS.
Follow-up transesophageal echocardiography after discharge from the hospital showed a
secundum atrial septal defect with a defect size of 1.8 cm. Right heart catheterization was
performed and the pulmonary flow to systemic flow (Qp/Qs) was 1.7:1 with a mean pulmonary
artery pressure of 21 mm Hg. An Amplatzer atrial septal defect (ASD) closure device was
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deployed with transesophageal echocardiographic guidance with successful closure of the defect.
At the patient’s request exchange red cell transfusions were discontinued. The patient continued
treatment with HU and aspirin. Repeat MRI of the brain after repair of the atrial septal defect
showed no acute infarction; there were discrete areas of encephalomalacia and gliosis in the deep
white matter of the frontal lobe corresponding to the areas of infarction identified previously. To
date, seven years after percutaneous repair of the atrial septal defect she has had no strokes.

Discussion
The most common cause of stroke in patients with SS is cerebral infarction in children and
hemorrhage in adults. The incidence of stroke in adult patients with SS, however, is not well
known and more studies are needed in this population [6] . Moreover, patients with SS are prone
to other causes of stroke such as cerebral infections, hyperlipidemia, renal disease, congenital
heart disease and hyperviscosity [6]. The role of HU in preventing or causing stroke is
controversial. Grace et al reported resolution of cerebral artery stenosis in a child with SS treated
with HU [7]. On the other hand, Sidani et al reported stroke in a patient with SS on HU and
hyperviscosity due to high Hb level after HU therapy [8]. In addition, the SWITCH study was
terminated early because of the increase in secondary stroke with HU [9]. Stroke due to
paradoxical embolism associated with congenital heart defect has been reported in patients with
SS sporadically. Dowling et al described an 11 year-old girl with recurrent bilateral, strokes
associated with patent foramen ovale, antiphospholipid antibodies and increased levels of factor
VIII and lipoprotein [5]. A combination of pulmonary arterial hypertension (PAH) and patent
foramen ovale may cause paradoxical embolization and stroke. However, stroke has been
reported in patients with patent foramen ovale in the presence or absence of PAH [10, 11] which
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is best defined by right heart catheterization (RHC) showing a mean pulmonary artery pressure ≥
25 mm Hg [12]. Our patient had a mean pulmonary artery pressure of 21 mm Hg by RHC thus
ruling out significant pulmonary hypertension. Moreover, atrial septal defect without stroke was
reported in a child with SS associated with successful closure of the defect with open heart
surgery [13].To the best of our knowledge , our patient seems to be the first patient with SS and
stroke due to paradoxical embolism secondary to atrial septal defect that did not require open
heart surgery for successful management.
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Table 1
Haematological parameters before and after hydroxyurea therapy

Parameters
Haemoglobin, g/dL
Hematocrit, %
Mean corpuscular volume, Fl
Mean corpuscular Hb, pg
Mean corpuscular Hb concentration
Reticulocyte count, %
Reticulocyte count, absolute
Fetal Hb, %
White blood cell count,
Platelets,

Before Hydroxyurea*
8.0
22.4
96
34.3
35.6
15.4
358,820/uL
6.1
15,800/uL
537,000/uL

*Baseline data before starting HU; †Data when presented with stroke

After Hydroxyurea†
9.8
30.2
132
39.1
32.5
5.3
123,500/uL
45
8,500/uL
452,000/uL

